Linezolid-Induced Serotonin Release from QGP-1 Cells

Area of Science:

• Pharmacology
• Gastroenterology
• Microbiology

Background:

• Linezolid is essential for treating multidrug-resistant tuberculosis and osteoarticular infections.
• Nausea and vomiting are common, yet poorly understood, side effects of long-term linezolid treatment.
• The mechanism of linezolid-induced emesis is unknown, prompting investigation into its monoamine oxidase-inhibiting properties.

Purpose of the Study:

• To investigate the mechanism of nausea and vomiting associated with linezolid therapy.
• To explore the role of serotonin release in linezolid-induced emesis.
• To determine if linezolid's monoamine oxidase-inhibiting effect contributes to serotonin release.

Main Methods:

• In vitro serotonin release assays using QGP-1 cells, a surrogate for enterochromaffin cells.
• Exposure of cells to linezolid, clorgyline (a monoamine oxidase inhibitor), and cisplatin (an emetogenic agent).
• Measurement of serotonin concentrations via ELISA and assessment of intracellular calcium levels using Fura-2 assays.

Main Results:

• Linezolid significantly increased serotonin release from QGP-1 cells in a concentration- and time-dependent manner.
• Co-exposure with clorgyline enhanced serotonin release compared to single exposures, suggesting a synergistic effect.
• Linezolid-induced serotonin release occurred independently of intracellular calcium changes, indicating a non-exocytotic mechanism.

Conclusions:

• Linezolid induces serotonin release from enterochromaffin cells, potentially explaining its emetogenic side effects.
• The mechanism of linezolid-induced serotonin release is independent of calcium-dependent exocytosis.
• Further research is warranted to elucidate the precise molecular pathways involved in linezolid-induced nausea and vomiting.